Risk factor grading for prevention of coronary artery disease;Präivention der KHK durch risikostratifizierung: Eine neue sichtweise mit konsequenzen für die gesundheitsfürsorge

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 7, 2003, Pages 330-336

  Erbel, R ^a   Siffert, W ^a   Mohlenkamp S ^a   Schmermund, A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; HEART VENTRICLE EJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; MORTALITY; OBESITY; PRIMARY PREVENTION; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CULTURAL FACTOR; FEMALE; GERMANY; MALE; MIDDLE AGED; SUDDEN DEATH; SURVIVAL RATE;

ADULT; AGED; CAUSE OF DEATH; CORONARY DISEASE; CROSS-CULTURAL COMPARISON; DEATH, SUDDEN, CARDIAC; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE;

EID: 0037435774     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37249     Document Type: Review

References (65)

1. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-315
2. Cowie MR. Coronary risk - time for a more sophisticated approach? Eur Heart J 2002; 23: 589-591
3. Cremer P, Nagel D, Mann H et al. Ten-year follow-up results from the Göttingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997; 129: 221-230
4. Critchley JA, Capewell S. Why model coronary heart disease? Eur Heart J 2002; 23: 110-116
5. Cullen P, Assmann G. Primäre und sekundäre Prävention der koronaren Herzerkrankung. Ein Positionspapier der Internationalen Task Force for Prevention of Coronary Heart Disease. Dtsch Med Wochenschr 2000; 125: 881-887
6. D'Agostino RB, Grundy S, Sullivan LM, Wilson P CHD risk prediction group. Validation of the Framingham coronary heart disease prediction score: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187
7. Dahlof B, Devereux RB, Kjeldsen S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003
8. Dawber TR, Kannel WB. The Framingham Study: An epidemiological approach to coronary heart disease. Circulation 1966; 34: 553-555
9. Deckers JW. Towards prevention, and not just postponement, of atherosclerotic disease. Eur Heart J 2002; 23: 771-773
10. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000; 23: 1619-1629
11. Duckworth WC. Hyperglycemia and cardiovascular disease. Current Atherosclerosis Rep 2001; 3: 383-391
12. Erbel R, Schmermund A, Möhlenkamp S, Sack S, Baumgart D. Electron-beam computed tomography for detection of early signs of coronary arteriosclerosis. Eur Heart J 2000; 21: 720-732
13. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients form 15 countries; principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554
14. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity US adults, 1999-2000. JAMA 2002; 288: 1723-1727
15. Fuller JH, Shipley MJ, Rose G et al. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ 1983; 287: 867-870
16. Garg J, Messerli AW, Bakris GL. Evaluation and Treatment of Patients With Systemic Hypertension. Circulation 2002; 105: 2458-2461
17. Greenland P, Abrams J, Aurigemma GP et al. Prevention Conference V. Beyond secondary prevention, identifying the high-risk patient for primary prevention. Noninvasive tests of atherosclerotic burden. Writing Group III. Circulation 2000; 101: e16-e22
18. Grundy SM. Primary prevention of coronary heart disease. Integrating risk assessment with intervention. Circulation 1999; 100: 988-998
19. Grundy SM, Bazzarre T, Cleeman J et al. Prevention Conference V. Beyond secondary prevention, identifying the high-risk patient for primary prevention. Medical office assessment. Writing Group I. Circulation 2000; 101: E3-E11
20. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
21. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease - a meta-analysis of epidemiologic studies. N Engl J Med 1999; 340: 920-926
22. Heart Protection Study Collaborative Group. Heart Protection Study of Cholesterol lowering with simvastatin in 20 536 high - risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
23. Heidrich J, Liese AD. Kalic M et al. Sekundärprävention der koronaren Herzkrankheit. Ergebnisse der EUROSPIRE I und II Studien in der Region Münster. Dtsch Med Wochenschr 2002; 127: 667-669
24. The HOPE Investigators. Effects of an ACE-inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study. N Engl J Med 2000; 342: 145-153
25. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-1482
26. Kesteloot H, Sans S, Kromhout D. Evolution of all-causes and cardiovascular mortality in the age group 75-84 years in Europe in the world 1970-1996. A comparison with worldwide changes. Eur Heart J 2002; 22: 384-398
27. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Typ 2 Diabetes with liefestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
28. Kritz H. Schmid P, Sinzinger H. Passive smoking and cardiovascular risk. Arch Int Med 1995; 155: 1942-1948
29. Kuch B, Bolte HD, Hoermann A, Meisinger C, Loewel H. What ist the real hospital mortality from acute myocardial infarction? Eur Heart J 2002; 23: 714-720
30. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J, 2002; 23: 706-713
31. Löwel H, Meisinger C, Heier M et al. Geschlechtsspezifische Trends von plötzlichem Herztod und akutem Herzinfarkt. Dtsch Med Wochenschr 2002; 127: 2311-2316
32. Mokdad AH, Bowman BA, Ford ES et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200
33. Mokdad AH, Serdula MK, Dietz WH et al. The continuing epidemic of obesity in the United States. JAMA 2000; 284: 1650-1651
34. Mokdad AH, Ford ES, Bowman BA et al. Diabetes trends in the US: 1990-1998 (comment). Diabetes Care 2000; 23: 1278-1283
35. Muscholl MW, Hense HW, Brockel U, Doring A, Riegger GA. Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey. BMJ 1998; 317: 565-70
36. NECP. Executive Summary of The Third Report of The National Cholesterol Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
37. Ockene JK, Kuller LH, Svendsen KH, Meilahn E. The relationship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Tiral (MRFIT). Am J Public Health 1990; 80: 954-958
38. Qiao Q, Pyorala K, Pyorala M et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 16: 1267-1275
39. Pyörälä K, Wood D. Prevention of coronary heart disease in clinical practise. European recommendations revised and reinforced. Eur Heart J 1998; 19: 1413-1415
40. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818
41. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002; 23: 794-799
42. Rigat B, Hubert C, Alhence-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin-1 converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346
43. Rodriguez-Artalejo F, Guallar-Castillón P, Banegas JR, Gutiérrez-Fisac JL, del Rey Calero J. The association between mortality from ischaemic heart disease and mortality from leading chronic diseases. Eur Heart J 2000; 21: 1841-1852
44. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001; 24: 447-453
45. Schmermund A, Baumgart D, Görge G et al. Measuring the effect of risk factors on coronary atherosclerosis: coronary calcium score versus angiographic disease severity. J Am Coll Cardiol 1998; 31: 1267-1273
46. Schmermund A, Erbel R. New concepts of primary prevention require rethinking. Med Klin 2001; 96: 261-269
47. Schmermund A, Möhlenkamp S, Stang A et al. for the Heinz Nixdorf Recall Study Investigative Group. Assessment of Clinically Silent Atherosclerotic Disease and Established and Novel Risk Factors for Predicting Myocardial Infarction and Cardiac Death in Healthy Middle-Aged Subjects: Rationale and Design of the Heinz Nixdorf Recall Study. Am Heart J 2002; 144: 212-218
48. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. Eur Heart J 2002; 23: 620-626
49. Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation 2001; 104: 393-398
50. Siegrist J, Peter R. The model of effort-reward imbalance. PhiladelphiaHanley and Belfus Publishers, In: Schnall P, Belkic K, Landsbergis P, Baker D, (eds). The workplace and cardiovascular disease. 1999: 83-87
51. Siffert W, Forster P, Joeckel KH et al. Worldwide ethnic distribution of the G protein β3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999; 10: 1921-1930
52. Smith SC, Blair SN, Bonow RO et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol 2001; 38: 1581-1583
53. Stamler J, Stamler R, Neaton JD et al. Low risk factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy. Findings for 5 large cohorts of young adult and middle - age men and women. JAMA 1999; 282: 2012-2018
54. Temelkova-Kurktschiev T, Fischer S et al. Intima-Media-Dicke bei Gesunden ohne Risikofaktoren für Arteriosklerose. Dtsch Med Wochenschr 2001; 126: 193-196
55. Tiret L, Rigat B, Visvikis S et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205
56. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-1557
57. Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al. Estimation of contribution of changes in coronary care to improving survival, even rates, and coronary heart disease mortalita across the WHO MONICA populations. Lancet 2000; 355: 688-700
58. Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischemic heart disease in Finland. Br Med J 1994; 309: 23-27
59. Verdecchia P, Schillaci G, Borgioni C, Gattobigio R, Ambrosio G, Porcellati C. Prevalent influence of systolic over pulse pressure on left ventricular mass in essential hypertension. Eur Heart J 2002; 23: 658-665
60. Willich SN, Löwel H, Mey W, Trautner C. Regionale Unterschiede der Herz-Kreislauf-Mortalität in Deutschland. Dt Ärztebl 1999; 96: A483-488; Berichtigung A-635
61. Wood DA, de Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270
62. Yusuf S, Reddy S, Ounpuu S, Anand S. Global Burden of Cardiovascular Diseases. Part I: General Considerations, the Epidemiologic Transition, Risk Factors and Impact of Urbanization. Circulation 2001; 104: 2746-2753
63. Yusuf S, Reddy S, Ounpuu S, Anand S. Global Burden of Cardiovascular Diseases. Part II: Variations in Cardiovascular Disease by Specific Ethnic Groups and Geographic Regions and Prevention Strategies. Circulation 2001; 104: 2855-2864
64. Zheng ZJ, Croft JB, Wayne HG, Mensah GA. Sudden Cardiac Death in the United States, 1989 to 1998. Circulation 2001; 104: 2158-2163
65. Zipes DP, Wellens HJJ. Sudden Cardiac Death. Circulation 1998; 98: 2334-2351